Get the Stockscreener App
1.76
0.56%
-0.01
After Hours:
1.75
-0.01
-0.57%
Atyr Pharma Inc stock is traded at $1.76, with a volume of 103.72K.
It is down -0.56% in the last 24 hours and down -5.88% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$1.77
Open:
$1.74
24h Volume:
103.72K
Relative Volume:
0.29
Market Cap:
$133.40M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.56%
1M Performance:
-5.88%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.74
$1.79
1-Week Range:
$1.72
$1.8099
52-Week Range:
$1.42
$2.50
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Atyr Pharma Inc Stock (ATYR) Latest News
Wall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risks - Investing.com
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5% - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Aarti Drugs gets 7 observation from USFDA for Tarapur plant - NewsDrum
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
A look into Atricure Inc (ATRC)’s deeper side - SETE News
First Light Asset Management LLC Grows Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Aarti Drugs shares trade lower after 7 observations from USFDA - Moneycontrol
Buying Buzz: Atyr Pharma Inc [ATYR] Director SCHIMMEL PAUL purchases 52,300 shares of the company - Knox Daily
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Atyr PHARMA (ATYR) versus Its Competitors Critical Survey - Defense World
Aster DM Health, Quality CARE inching closer to a merger deal - The Economic Times
Atyr PHARMA (ATYR) and Its Rivals Head to Head Analysis - Defense World
Atyr PHARMA (NASDAQ:ATYR) versus Exscientia (NASDAQ:EXAI) Critical Survey - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat
Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily
ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily
Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News
Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex
Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN
Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World
Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News
Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World
Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World
Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK
aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences - StockTitan
ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com
Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com
Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex
aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com
ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com
Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):